Skip to main content

CORRECTION article

Front. Stroke, 29 January 2024
Sec. Acute Stroke and Interventional Therapies
Volume 3 - 2024 | https://doi.org/10.3389/fstro.2024.1371734

Corrigendum: Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke

This article is a correction to:

  1. Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke

    1. Read original article
\r\nElizabeth S. Fisher&#x;Elizabeth S. Fisher1†Yanan Chen&#x;Yanan Chen1†Mikaela M. Sifuentes&#x;Mikaela M. Sifuentes1†Jeremy J. StubblefieldJeremy J. Stubblefield1Damian LozanoDamian Lozano1Deborah M. HolsteinDeborah M. Holstein1JingMei RenJingMei Ren2Matthew DavenportMatthew Davenport2Nicholas DeRosaNicholas DeRosa1Tsung-pei ChenTsung-pei Chen1Gerard NickelGerard Nickel1Theodore E. ListonTheodore E. Liston3James D. Lechleiter James D. Lechleiter1*
  • 1Department of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX, United States
  • 2NeuroVasc Preclinical Services, Inc., Lexington, MA, United States
  • 3Astrocyte Pharmaceuticals Inc., Cambridge, MA, United States

A corrigendum on
Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke

by Fisher, E. S., Chen, Y., Sifuentes, M. M., Stubblefield, J. J., Lozano, D., Holstein, D. M., Ren, J., Davenport, M., DeRosa, N., Chen, T. -p., Nickel, G., Liston, T. E., and Lechleiter, J. D. (2022). Front. Stroke 1:1010928. doi: 10.3389/fstro.2022.1010928

In the published article, there was an error in the Funding statement. The funding source for coauthor Jeremy J. Stubblefield was not included. Original text: This study received funding from Astrocyte Pharmaceuticals, Inc. The correct Funding statement appears below.

Funding

This study received funding from Astrocyte Pharmaceuticals, Inc. JS was supported by NIH IRACDA training grant K12 GM111726.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Adora3, stroke treatment, mitochondrial metabolism, ATP, astrocytes

Citation: Fisher ES, Chen Y, Sifuentes MM, Stubblefield JJ, Lozano D, Holstein DM, Ren J, Davenport M, DeRosa N, Chen T-p, Nickel G, Liston TE and Lechleiter JD (2024) Corrigendum: Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke. Front. Stroke 3:1371734. doi: 10.3389/fstro.2024.1371734

Received: 16 January 2024; Accepted: 18 January 2024;
Published: 29 January 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Fisher, Chen, Sifuentes, Stubblefield, Lozano, Holstein, Ren, Davenport, DeRosa, Chen, Nickel, Liston and Lechleiter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: James D. Lechleiter, lechleiter@uthscsa.edu

†These authors share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.